Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer

Journal of Proteome Research

Volumn 11, Issue 9, 2012, Pages 4605-4614

  Chappell, Nicole P ^a,b   Teng, Pang Ning ^b   Hood, Brian L ^b   Wang, Guisong ^b   Darcy, Kathleen M ^b   Hamilton, Chad A ^a,b   Maxwell, G Larry ^b,c   Conrads, Thomas P ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

cisplatin; mitochondria; ovarian cancer; proteomics; resistance

Indexed keywords

A KINASE ANCHORING PROTEIN 12; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CISPLATIN; MITOCHONDRIAL PROTEIN; NESTIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL SURVIVAL; CELLULAR DISTRIBUTION; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; METASTASIS; MITOCHONDRION; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

A KINASE ANCHOR PROTEINS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES, NEURONAL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FETAL PROTEINS; HUMANS; IMMUNOBLOTTING; INTERMEDIATE FILAMENT PROTEINS; INTRACELLULAR SPACE; MITOCHONDRIAL PROTEINS; NERVE TISSUE PROTEINS; OVARIAN NEOPLASMS; PROTEIN INTERACTION MAPS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE;

EID: 84866125839     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300403d     Document Type: Article

References (52)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012 CA-Cancer J. Clin. 2012, 62 (1) 10-29
2. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 2003, 22 (47) 7265-79 (Pubitemid 37487159)
3. F., M. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer Gynecol. Oncol. 2009, 112 (1) 5
4. Borst, P.; Rottenberg, S.; Jonkers, J. How do real tumors become resistant to cisplatin? Cell Cycle 2008, 7, 1353-59 (Pubitemid 351872573)
5. Jelovac, D.; Armstrong, D. K. Recent progress in the diagnosis and treatment of ovarian cancer CA-Cancer J. Clin. 2011, 61 (3) 183-203
6. Berkenblit, A.; Cannistra, S. Advances in the management of epithelial ovarian cancer J. Reprod. Med. 2005, 50 (6) 426-38 (Pubitemid 40863959)
7. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma Nature 2011, 474 (7353) 609-15
8. Stewart, D. Mechanisms of resistance to cisplatin and carboplatin Crit. Rev. Oncol. Hematol. 2007, 63 (1) 12-31 (Pubitemid 46810280)
9. Gore, M. E.; Fryatt, I.; Wiltshaw, E.; Dawson, T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol. Oncol. 1990, 36 (2) 207-11 (Pubitemid 20061287)
10. Rustin, G. J. S.; Van der Burg, M. E. L.; Griffin, C. L.; Guthrie, D.; Lamont, A.; Jayson, G. C.; Kristensen, G.; Mediola, C.; Coens, C.; Qian, W.; Parmar, M. K. B.; Swart, A. M. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 2010, 376 (9747) 1155-63
11. Agarwal, R.; Kaye, S. Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat. Rev. Cancer 2003, 3 (7) 502-16 (Pubitemid 37328838)
12. Hirama, M.; Isonishi, S.; Yasuda, M.; Ishikawa, H. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells Oncol. Rep. 2006, 16 (5) 997-1002
13. Rabik, C.; Dolan, M. Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat. Rev. 2007, 33 (1) 9-23 (Pubitemid 46137553)
14. Sedletska, Y.; Giraud-Panis, M.; Malinge, J. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways Curr. Med. Chem. Anticancer Agents 2005, 5 (3) 251-65 (Pubitemid 40655276)
15. Hall, M.; Okabe, M.; Shen, D.; Liang, X.; Gottesman, M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy Annu. Rev. Pharmacol. Toxicol. 2008, 48, 495-535 (Pubitemid 351738162)
16. Verma, M.; Kagan, J.; Sidransky, D.; Srivastava, S. Proteomic analysis of cancer-cell mitochondria Nat. Rev. Cancer 2003, 3 (10) 789-95 (Pubitemid 37328817)
17. Hendrickson, S. L.; Lautenberger, J. A.; Chinn, L. W.; Malasky, M.; Sezgin, E.; Kingsley, L. A.; Goedert, J. J.; Kirk, G. D.; Gomperts, E. D.; Buchbinder, S. P.; Troyer, J. L.; O'Brien, S. J. Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression PLoS One 2010, 5 (9) e12862
18. Ralph, S. J.; Rodriguez-Enriquez, S.; Neuzil, J.; Saavedra, E.; Moreno-Sanchez, R. The causes of cancer revisited: ″mitochondrial malignancy″ and ROS-induced oncogenic transformation-why mitochondria are targets for cancer therapy Mol. Aspects Med. 2010, 31 (2) 145-70
19. Kulawiec, M.; Owens, K. M.; Singh, K. K. Cancer cell mitochondria confer apoptosis resistance and promote metastasis Cancer Biol. Ther. 2009, 8 (14) 1378-85
20. Calvo, S. E.; Mootha, V. K. The mitochondrial proteome and human disease Annu. Rev. Genomics Hum. Genetics 2010, 11 (1) 25-44
21. Sylvestre, J.; Margeot, A.; Jacq, C.; Dujardin, G.; Corral-Debrinski, M. The role of the 3′ untranslated region in mRNA sorting to the vicinity of mitochondria is conserved from yeast to human cells Mol. Biol. Cell 2003, 14 (9) 3848-56 (Pubitemid 37151630)
22. Lescuyer, P.; Strub, J. M.; Luche, S.; Diemer, H.; Martinez, P.; Van Dorsselaer, A.; Lunardi, J.; Rabilloud, T. Progress in the definition of a reference human mitochondrial proteome Proteomics 2003, 3 (2) 157-67 (Pubitemid 36254598)
23. Hamilton, T. C.; Young, R. C.; McKoy, W. M.; Grotzinger, K. R.; Green, J. A.; Chu, E. W.; Whang-Peng, J.; Rogan, A. M.; Green, W. R.; Ozols, R. F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors Cancer Res. 1983, 43 (11) 5379-89 (Pubitemid 14230154)
24. Buick, R. N.; Pullano, R.; Trent, J. M. Comparative properties of five human ovarian adenocarcinoma cell lines Cancer Res. 1985, 45 (8) 3668-76 (Pubitemid 15226443)
25. Jo, U.; Whang, Y. M.; Kim, H. K.; Kim, Y. H. AKAP12alpha is associated with promoter methylation in lung cancer Cancer Res. Treat. 2006, 38 (3) 144-51
26. Liu, Y.; Gao, L.; Gelman, I. SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis BMC Cancer 2006, 6 (1) 105
27. Yeh, P.; Chuang, S.; Yeh, K.; Song, Y.; Ea, C.; Cheng, A. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation Biochem. Pharmacol. 2002, 63 (8) 1423-30 (Pubitemid 34457957)
28. Choi, M. C.; Jong, H. S.; Kim, T. Y.; Song, S. H.; Lee, D. S.; Lee, J. W.; Kim, N. K.; Bang, Y. J. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity Oncogene 2004, 23 (42) 7095-103 (Pubitemid 39319171)
29. Wikman, H.; Kettunen, E.; Seppanen, J. K.; Karjalainen, A.; Hollmen, J.; Anttila, S.; Knuutila, S. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array Oncogene 2002, 21 (37) 5804-13 (Pubitemid 35333015)
30. Gelman, I. H. Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis Genes Cancer 2010, 1 (11) 1147-56
31. Akakura, S.; Nochajski, P.; Gao, L.; Sotomayor, P.; Matsui, S.-i.; Gelman, I. H. Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12 Cell Cycle 2010, 9 (23) 4656-65
32. King, J. A. Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer Mol. Cancer 2010, 9, 266
33. Alvero, A. B.; Montagna, M. K.; Holmberg, J. C.; Craveiro, V.; Brown, D.; Mor, G. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells Mol. Cancer Ther. 2011, 10 (8) 1385-93
34. Wang, C. Y.; Cusack, J. C., Jr.; Liu, R.; Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB Nat. Med. 1999, 5 (4) 412-7 (Pubitemid 29180579)
35. Kleeberger, W; B., G.; Nielsen, M. E.; Herawi, M Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis Cancer Res. 2007, 67 (19) 9199-206 (Pubitemid 47535906)
36. Jia, Y; W., S.; Isenberg, J. S.; Dai, S; Sipes, J. M.; Roberts, D. D. Thiolutin inhibits endothelial cell adhesion by perturbing Hsp27 interactions with components of the actin and intermediate filament cytoskeleton Cell Stress Chaperones 2010, 15 (2) 165-81
37. Bergstrom, D. A.; Penn, B. H.; Strand, A.; Perry, R. L.; Rudnicki, M. A.; Tapscott, S. J. Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression Mol. Cell 2002, 9 (3) 587-600 (Pubitemid 34273789)
38. Matsuda, Y.; Naito, Z.; Kawahara, K.; Nakazawa, N.; Korc, M.; Ishiwata, T. Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis Cancer Biol. Ther. 2011, 11 (5) 512-23
39. Teranishi, N.; Naito, Z.; Ishiwata, T.; Tanaka, N.; Furukawa, K.; Seya, T.; Shinji, S.; Tajiri, T. Identification of neovasculature using nestin in colorectal cancer Int. J. Oncol. 2007, 30 (3) 593-603
40. Ishiwata, T.; Matsuda, Y; Naito, Z. Nestin in gastrointestinal and other cancers: Effects on cells and tumor angiogenesis World J. Gastroenterol. 2011, 17 (4) 409-18
41. Teoh, D.; Secord, A. A. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer Int. J. Gynecol. Cancer 2012, 22 (3) 348-59
42. Perren, T. J.; Swart, A. M.; Pfisterer, J.; Ledermann, J. A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M. S.; Beale, P.; Cervantes, A.; Kurzeder, C.; du Bois, A.; Sehouli, J.; Kimmig, R.; Stahle, A.; Collinson, F.; Essapen, S.; Gourley, C.; Lortholary, A.; Selle, F.; Mirza, M. R.; Leminen, A.; Plante, M.; Stark, D.; Qian, W.; Parmar, M. K.; Oza, A. M. A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 2011, 365 (26) 2484-96
43. Hu, Y.; Rosen, D. G.; Zhou, Y.; Feng, L.; Yang, G.; Liu, J.; Huang, P. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer J. Biol. Chem. 2005, 280 (47) 39485-92
44. Araujo, J.; Breuer, P.; Dieringer, S.; Krauss, S.; Dorn, S.; Zimmermann, K.; Pfeifer, A.; Klockgether, T.; Wuellner, U.; Evert, B. O. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3 Hum. Mol. Genet. 2011, 20 (15) 2928-41
45. Dai, R.; Yan, D.; Li, J.; Chen, S.; Liu, Y.; Chen, R.; Duan, C.; Wei, M.; Li, H.; He, T. Activation of PKR/eIF2α signaling cascade is associated with dihydrotestosterone-induced cell cycle arrest and apoptosis in human liver cells J. Cell. Biochem. 2012, 113 (5) 1800-8
46. Kravtsova-Ivantsiv, Y.; Ciechanover, A. Non-canonical ubiquitin-based signals for proteasomal degradation J. Cell Sci. 2012, 125 (3) 539-48
47. Takaoka, A.; Wang, Z.; Choi, M. K.; Yanai, H.; Negishi, H.; Ban, T.; Lu, Y.; Miyagishi, M.; Kodama, T.; Honda, K.; Ohba, Y.; Taniguchi, T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response Nature 2007, 448 (7152) 501-5 (Pubitemid 47123520)
48. Nikiforov, A.; Dölle, C.; Niere, M.; Ziegler, M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells J. Biol. Chem. 2011, 286 (24) 21767-78
49. Yue, X. L.; Lehri, S.; Li, P.; Barbier-Chassefiere, V.; Petit, E.; Huang, Q. F.; Albanese, P.; Barritault, D.; Caruelle, J. P.; Papy-Garcia, D.; Morin, C. Insights on a new path of pre-mitochondrial apoptosis regulation by a glycosaminoglycan mimetic Cell Death Differ. 2009, 16 (5) 770-81
50. Afratis, N.; Gialeli, C.; Nikitovic, D.; Tsegenidis, T.; Karousou, E.; Theocharis, A. D.; Pavão, M. S.; Tzanakakis, G. N.; Karamanos, N. K. Glycosaminoglycans: key players in cancer cell biology and treatment FEBS J. 2012, 279 (7) 1177-97
51. Wallace, D. C. Mitochondria and cancer: Warburg addressed Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 363-74 (Pubitemid 44124891)
52. Modica-Napolitano, J. S.; Singh, K. K. Mitochondrial dysfunction in cancer Mitochondrion 2004, 4 (5-6) 755-62 (Pubitemid 39646820)